Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery

被引:13
|
作者
Patel, Dipal M. [1 ]
Thiessen-Philbrook, Heather [2 ]
Brown, Jeremiah R. [3 ,4 ,5 ]
McArthur, Eric [6 ]
Moledina, Dennis G. [1 ,7 ]
Mansour, Sherry G. [1 ,7 ]
Shlipak, Michael G. [8 ,9 ,10 ]
Koyner, Jay L. [11 ]
Kavsak, Peter [12 ,13 ]
Whitlock, Richard P. [14 ,15 ]
Everett, Allen D. [16 ]
Malenka, David J. [3 ,4 ,5 ]
Garg, Amit X. [6 ,17 ]
Coca, Steven G. [18 ]
Parikh, Chirag R. [2 ]
机构
[1] Yale Univ, Sch Med, Dept Med, Program Appl Translat Res, New Haven, CT 06510 USA
[2] Johns Hopkins Univ, Sch Med, Div Nephrol, Baltimore, MD USA
[3] Geisel Sch Med, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA
[4] Geisel Sch Med, Dept Biomed Data Sci, Lebanon, NH USA
[5] Geisel Sch Med, Dept Epidemiol, Lebanon, NH USA
[6] ICES, Toronto, ON, Canada
[7] Yale Univ, Sch Med, Sect Nephrol, New Haven, CT USA
[8] Univ Calif San Francisco, Kidney Hlth Res Collaborat, San Francisco, CA 94143 USA
[9] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA
[10] Univ Calif San Francisco, San Francisco, CA 94143 USA
[11] Univ Chicago, Pritzker Sch Med, Dept Med, Sect Nephrol, Chicago, IL 60637 USA
[12] McMaster Univ, Dept Pathol, Hamilton, ON, Canada
[13] McMaster Univ, Dept Mol Med, Hamilton, ON, Canada
[14] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
[15] McMaster Univ, Dept Surg, Hamilton, ON, Canada
[16] Johns Hopkins Sch Med, Dept Pediat, Div Cardiol, Baltimore, MD USA
[17] Western Univ, Dept Med, Div Nephrol, London, ON, Canada
[18] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
2013 ACCF/AHA GUIDELINE; RECEPTOR FAMILY-MEMBER; ACUTE KIDNEY INJURY; HEART-FAILURE; CLINICAL-APPLICATIONS; AMERICAN-COLLEGE; TASK-FORCE; BIOMARKERS; FIBROSIS; RISK;
D O I
10.1016/j.ahj.2019.11.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cardiac surgery induces hemodynamic stress on the myocardium, and this process can be associated with significant post-operative morbidity and mortality. Soluble suppression of tumorigenicity 2 (sST2) and galectin-3 (gal-3) are biomarkers of myocardial remodeling and fibrosis; however, their potential association with post-operative changes is unknown. Methods We measured peri-operative plasma sST2 and gal-3 levels in two prospective cohorts (TRIBE-AKI and NNE) of over 1800 patients who underwent cardiac surgery. sST2 and gal-3 levels were evaluated for association with a composite primary outcome of cardiovascular event or mortality over median follow-up periods of 3.4 and 6.0 years, respectively, for the two cohorts. Meta-analysis of hazard ratio estimates from the cohorts was performed using random effects models. Results Cohorts demonstrated event rates of 70.2 and 66.8 per 1000 person-years for the primary composite outcome. After adjustment for clinical covariates, higher post-operative sST2 and gal-3 levels were significantly associated with cardiovascular event or mortality [pooled estimate HRs: sST2 1.29 (95% CI 1.16, 1.44); gal-3 1.26 (95% CI 1.09, 1.46)]. These associations were not significantly modified by pre-operative congestive heart failure or AKI. Conclusions Higher postoperative sST2 and gal-3 values were associated with increased incidence of cardiovascular event or mortality. These two biomarkers should be further studied for potential clinical utility for patients undergoing cardiac surgery.
引用
收藏
页码:253 / 263
页数:11
相关论文
共 50 条
  • [21] Soluble ST2, Galectin-3 and clinical prognosis of patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy: a correlation analysis
    Song, Bangrong
    Yao, Bo
    Dang, Haiming
    Dong, Ran
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2020, 10 (02) : 145 - 152
  • [22] Association of ST2 levels with cardiac structure and function and mortality in outpatients
    Daniels, Lori B.
    Clopton, Paul
    Iqbal, Navaid
    Tran, Kimberly
    Maisel, Alan S.
    AMERICAN HEART JOURNAL, 2010, 160 (04) : 721 - 728
  • [23] Association of soluble ST2 with all-cause and cardiovascular mortality in renal transplant recipients: a single-centre cohort study
    Devine, Paul A.
    Cardwell, Christopher
    Maxwell, Alexander P.
    BMC NEPHROLOGY, 2020, 21 (01)
  • [24] Association of ST2, Galectin-3, and NT- Probnp in Elderly Hypertensive Patients and Heart Failure with a Preserved Ejection Fraction
    Li, Ping
    Wang, Lin
    Yang, Fan
    Yu, Hui
    Xiao, Fan Kai
    CURRENT VASCULAR PHARMACOLOGY, 2025,
  • [25] Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients
    Wojciechowska, Celina
    Romuk, Ewa
    Nowalany-Kozielska, Ewa
    Jachec, Wojciech
    HELLENIC JOURNAL OF CARDIOLOGY, 2017, 58 (05) : 350 - 359
  • [26] Interleukin 6, galectin 3, growth differentiation factor 15, and soluble ST2 for mortality prediction in critically ill patients
    Dieplinger, Benjamin
    Egger, Margot
    Leitner, Isabella
    Firlinger, Fritz
    Poelz, Werner
    Lenz, Kurt
    Haltmayer, Meinhard
    Mueller, Thomas
    JOURNAL OF CRITICAL CARE, 2016, 34 : 38 - 45
  • [27] Soluble ST2 plasma concentrations predict mortality in severe sepsis
    Hoogerwerf, Jacobien J.
    Tanck, Michael W. T.
    van Zoelen, Marieke A. D.
    Wittebole, Xavier
    Laterre, Pierre-Francois
    van der Poll, Tom
    INTENSIVE CARE MEDICINE, 2010, 36 (04) : 630 - 637
  • [28] Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes
    Lin, Ya-Hui
    Zhang, Rong-Cheng
    Hou, Li-Bo
    Wang, Kai-Juan
    Ye, Zhong-Ni
    Huang, Tao
    Zhang, Jian
    Chen, Xi
    Kang, Jin-Suo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 118 : 140 - 145
  • [29] Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis
    Pejnovic, Nada
    Jeftic, Ilija
    Jovicic, Nemanja
    Arsenijevic, Nebojsa
    Lukic, Miodrag L.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (44) : 9706 - 9717
  • [30] The emerging role of galectin-3 and ST2 in heart failure: Practical considerations and pitfalls using novel biomarkers
    Karayannis G.
    Triposkiadis F.
    Skoularigis J.
    Georgoulias P.
    Butler J.
    Giamouzis G.
    Current Heart Failure Reports, 2013, 10 (4) : 441 - 449